Naltrawave

Naltrexone is a synthetic, non-selective opioid receptor antagonist medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid use disorder and alcohol use disorder.[1][2] It competitively binds to mu-, kappa-, and delta-opioid receptors in the central nervous system with highest affinity for the mu receptor, thereby blocking the pharmacological effects of endogenous and exogenous opioids without activating the receptors itself.[3][4] Naltrexone is indicated as a maintenance treatment for alcohol use disorder in patients who have achieved abstinence following detoxification. It is not indicated for the treatment or prevention of acute alcohol withdrawal symptoms, which are typically managed with benzodiazepines or other supportive care.[3][5] In this context, naltrexone attenuates the rewarding and reinforcing effects of alcohol by antagonizing mu-opioid receptors, thereby blocking the binding of endogenous opioids such as beta-endorphins released during alcohol consumption, which reduces dopamine release in the mesolimbic reward pathway and diminishes alcohol's euphoric and reinforcing effects.[6][3] Initially approved in 1984 as an oral formulation (ReVia) for preventing relapse in detoxified opioid-dependent patients, its FDA approval was expanded in 1994 to include alcohol dependence, followed by the authorization of an extended-release intramuscular injectable form (Vivitrol) in 2006 for alcohol dependence and 2010 for opioid dependenc